Group PACBT for Depression
2026年4月28日 更新者:Marc J. Weintraub, PhD、University of California, Los Angeles
Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder
This study will seek to determine the (1) acceptability and (2) feasibility of psilocybin as an adjunct to cognitive-behavioral therapy, delivered as a group treatment (G-PACBT) for major depressive disorder and (3) explore the clinical effects of G-PACBT on depressive symptoms and psychosocial functioning.
研究概览
地位
尚未招聘
研究类型
介入性
注册 (估计的)
30
阶段
- 阶段2
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
California
-
Los Angeles、California、美国、90095
- UCLA Semel Institute
-
首席研究员:
- Marc Weintraub, PhD
-
接触:
- Shelby Grody
- 电话号码:3108254354
- 邮箱:UCLAPAT@mednet.ucla.edu
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
接受健康志愿者
不
描述
Inclusion Criteria:
- Ages 21-60,
- Fluent in English
- Able to swallow capsules,
- Meets for a current major depressive episode or a history of major depressive episodes based on the DSM-5 criteria (American Psychiatric Association, 2013),
- Active current depressive symptoms (i.e., scores >16 on the Hamilton-Depression Rating Scale covering the prior 2 weeks; Hamilton, 1986),
- Have an identified support person (i.e., trusted adult friend or relative) who can pick up the individual from UCLA Semel Institute and drive individual home following psilocybin sessions,
- For women of child-bearing potential - using one form of highly effective contraception (e.g., oral contraceptive pill) and willingness to continue contraceptive use for duration of study. Must be willing to take on-site pregnancy tests.
- Agree to refrain from any psychoactive drug (including alcohol) within 24 hours of each drug session and during the drug sessions. Participants will be allowed to consume their usual amount of caffeine prior to and after the drug sessions.
- Agree to not take any PRN medications on the mornings of the drug sessions
- Has been medically cleared for the study by a physician
- Participants must remain on anti-hypertensive medications if prescribed previously to manage hypertension
Exclusion Criteria:
- A personal or family history (first-degree) of psychosis or mania
- Resting blood pressure above 140 systolic, 90 diastolic or heart rate > 90 beats per minute (averaged across four separate measurements)
- Meeting criteria for a DSM-5 cluster B personality disorder (narcissistic, histrionic, borderline, antisocial personality disorder),
- Active suicidality (i.e., HAM-D item 3 score of greater than 3) or other psychiatric disturbance requiring acute treatment
- Current use of antidepressants or other serotonergic-affecting substances (e.g., St. John's Wort and 5-hydroxytryptophan), lithium, or efavirenz [regardless of whether the drug(s) is/are prescribed for MDD or other conditions]
- Current use of opioids (e.g., codeine, fentanyl, hydrocodone, meperidine, tramadol)
- Currently receiving cognitive behavioral therapy,
- Any of the following cardiovascular conditions: uncontrolled hypertension, coronary artery disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, tachycardia, artificial heart valve, a clinically significant screening ECG abnormality, or any other significant cardiovascular condition
- QTc interval measurement of > 450 ms in males or > 460 ms in females as measured by the baseline ECG
- A history of stroke or Transient Ischemic Attack (TIA)
- Epilepsy or history of seizures
- Insulin-dependent diabetes
- Meeting criteria for a DSM-5 substance abuse or dependence within prior 6 months (including for nicotine and cannabis)
- Positive urine drug screen for illicit substances (not including cannabis)
- Use of other psychedelics or ketamine within prior 12 months
- Adverse prior reaction to a 5-HT2A receptor agonist psychedelic agent
- Pregnant, trying to get pregnant, or nursing
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Group PACBT
12 sessions of PA-CBT (as manualized by our research team; Weintraub et al., 2023) and two administrations of psilocybin, administered orally (a 10mg dose followed by a 25mg dose one month later), all of which will be delivered in a group format whereby participants receive the treatments together and simultaneously
|
Two administrations of psilocybin, administered orally (a 10mg dose followed by a 25mg dose one month later)
12 sessions of PA-CBT (as manualized by our research team; Weintraub et al., 2023)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Treatment acceptability
大体时间:4 months (Baseline to Post-treatment)
|
Treatment acceptability as measured by the participant on the Client Satisfaction Questionnaire-8.
Total scores range from 8 to 32, with the higher number indicating greater satisfaction.
|
4 months (Baseline to Post-treatment)
|
|
Feasibility as measured by participant retention
大体时间:4 months
|
Participant retention over the treatment
|
4 months
|
|
Hamilton Depression Rating Scale
大体时间:7 months (Baseline to end of study)
|
Depressive symptom severity scored from 0-53, with larger values indicating greater depressive severity
|
7 months (Baseline to end of study)
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (估计的)
2027年1月1日
初级完成 (估计的)
2028年12月1日
研究完成 (估计的)
2028年12月1日
研究注册日期
首次提交
2026年4月28日
首先提交符合 QC 标准的
2026年4月28日
首次发布 (实际的)
2026年5月4日
研究记录更新
最后更新发布 (实际的)
2026年5月4日
上次提交的符合 QC 标准的更新
2026年4月28日
最后验证
2026年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.